Darunavir for use in pregnant women with HIV

References

• Global AIDS update 2016 [Internet]. Geneva: Joint United Nations Programme on HIV/AIDS; 2016 May 31. [cited 2016 Aug 25]. Available from: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf
   Google Scholar
• Prevention of mother-to-child transmission of HIV (PMTCT) and family planning (FP). Geneva: World Health Organization Department of Reproductive Health and Research. [cited 2016 Aug 25]. Available from: http://www.who.int/reproductivehealth/topics/linkages/pmtct/en/
   Google Scholar
• John GC, Kreiss J. Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev. 1996;18(2):149–157.
   PubMed Web of Science ®Google Scholar
• De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283(9):1175–1182.
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173–1180.
   PubMed Web of Science ®Google Scholar
• Siegfried N, van der Merwe L, Brocklehurst P, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011 July;6:7.
   Google Scholar
• Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353(9155):773–780.
   PubMed Web of Science ®Google Scholar
• Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet. 1999;353(9155):781–785.
   PubMed Web of Science ®Google Scholar
• Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795–802.
   PubMed Web of Science ®Google Scholar
• Kesho Bora Study Group; De Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–180.
   PubMed Web of Science ®Google Scholar
• Zaba B, Calvert C, Marston M, et al. Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA). Lancet. 2013;381(9879):1763–1771.
   PubMed Web of Science ®Google Scholar
• Calvert C, Ronsmans C. The contribution of HIV to pregnancy-related mortality: a systematic review and meta-analysis. AIDS. 2013;27(10):1631–1639.
   PubMed Web of Science ®Google Scholar
• Liotta G, Mancinelli S, Nielsen-Saines K, et al. Reduction of maternal mortality with highly active antiretroviral therapy in a large cohort of HIV-infected pregnant women in Malawi and Mozambique. PLoS One. 2013;8(8):e71653.
   PubMed Web of Science ®Google Scholar
• Global health sector response to HIV, 2000-2015. Geneva: World Health Organization; 2015 Nov. [cited 2016 Aug 25]. Available from: http://apps.who.int/iris/bitstream/10665/198065/1/9789241509824_eng.pdf?ua=1
   Google Scholar
• European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(3):458–465.
   PubMed Web of Science ®Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, et al. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. Bjog. 2008;115(9):1078–1086.
   PubMed Web of Science ®Google Scholar
• Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008;22(2):289–299.
   PubMed Web of Science ®Google Scholar
• Prieto LM, González-Tomé M, Muñoz E, et al. Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000-2007. Pediatr Infect Dis J. 2012;31(10):1053–1058.
   PubMed Web of Science ®Google Scholar
• Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville (MD): Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission; 2016 Jun 7. [cited 2016 Jul 21]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf
   Google Scholar
• Chougrani I, Luton D, Matheron S, et al. Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl). 2013;5:253–262.
   PubMedGoogle Scholar
• Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2016. 2016. Wilmington (NC): Registry Coordinating Center. [cited 2016 Jul 21]. Available from: www.APRegistry.com
   Google Scholar
• Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47(10):3123–3129.
   PubMed Web of Science ®Google Scholar
• De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314–2321.
   PubMed Web of Science ®Google Scholar
• Prezista (darunavir) [US package insert]. Titusville (NJ): Janssen Pharmaceuticals; 2016 Jun Revised.
   Google Scholar
• Prezista (darunavir) [EU summary of product characteristics]. Latina; Janssen-Cilag SpA; 2013 Sep. Revised.
   Google Scholar
• Andany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. Drugs. 2013;73(3):229–247.
   PubMed Web of Science ®Google Scholar
• Griner R, Williams PL, Read JS, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS. 2011;25(7):385–394.
   PubMed Web of Science ®Google Scholar
• Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville (MD): Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission; 2004 Jun 23. [cited 2016 Jul 21]. Available from: https://aidsinfo.nih.gov/ContentFiles/PerinatalGL06232004029.pdf
   Google Scholar
• Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville (MD): Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission; 2007 Nov 2. [cited 2016 Jul 21]. Available from: http://aidsinfo.nih.gov/contentfiles/PerinatalGL02112007901.pdf
   Google Scholar
• Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville (MD): Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission; 2012 Jul 31. [cited 2016 Jul 21]. Available from: http://aidsinfo.nih.gov/contentfiles/PerinatalGL003171.pdf
   Google Scholar
• Mills AM, Nelson M, Jayaweera D. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1 infected patients: 96-week analysis. AIDS. 2009;23(13):1679–1688.
   Google Scholar
• Cahn P, Fourie J, Grinsztejn B. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929–939.
   Google Scholar
• Bánhegyi D, Katlama C, Da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in titan. Curr Hiv Res. 2012;10(2):171–181.
   PubMed Web of Science ®Google Scholar
• De Meyer S, Dierynck I, Lathouwers E, et al. Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced subjects in POWER 1, 2, 3 and DUET-1 and DUET-2. In: 6th European HIV Drug Resistance Workshop; 2008 Mar 26-28; Budapest, Hungary. Abstract 45.
   Google Scholar
• Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol. 1992;45(1):27–35.
   PubMed Web of Science ®Google Scholar
• Zorrilla CD, Wright R, Oisyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunvair/ritonavir 600/100 mg administered twice daily. HIV Med. 2014;15(1):50–56.
   PubMed Web of Science ®Google Scholar
• Crauwels HM, Kakuda TN, Ryan B, et al. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women. HIV Med. 2016;17(9):643–652.
   PubMed Web of Science ®Google Scholar
• De Meyera S, Lathouwersa E, Dieryncka I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 2009;23:1829–1840.
   PubMed Web of Science ®Google Scholar
• Tasnif Y, Morado J, Hebert MF. Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther. 2016;100(1):53–62.
   PubMed Web of Science ®Google Scholar
• Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci. 2000;918:287–297.
   PubMed Web of Science ®Google Scholar
• Colbers A, Moltó J, Ivanovic J, et al. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. J Antimicrob Chemother. 2015;70(2):534–542.
   PubMed Web of Science ®Google Scholar
• Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16(1):99–108.
   PubMed Web of Science ®Google Scholar
• Lambert J, Jackson V, Else L, et al. Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc. 2014;17(4 Supp 3):19485.
   PubMedGoogle Scholar
• Stek A, Best BM, Wang J, et al. Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women. J Acquir Immune Defic Syndr. 2015;70(1):33–41.
   PubMed Web of Science ®Google Scholar
• Le M, Blondel L, Charpentier C, et al. Pharmacokinetic, safety and efficacy of darunavir/ritonavir in HIV+ pregnant women. In: 17th International workshop on clinical pharmacology of HIV and hepatitis therapy; 2012 Jun 8-10; Washington (DC). Abstract #O-01.
   Google Scholar
• Courbon E, Matheron S,  Mandelbrot L, et al. Safety, efficacy, and pharmacokinetic of darunavir/ritonavir-containing regimen in pregnant HIV+ women. In: Paper presented at: 19th conference on retroviruses and opportunistic infections (CROI); 2012 Mar 5-8; Seattle (WA). Abstract #1011.
   Google Scholar
• Stek A, Best BM, Capparelli E, et al. Pharmacokinetics of increased dose darunavir during late pregnancy and postpartum. In: Paper presented at: 23rd conference on retroviruses and opportunistic infections (CROI); 2016 Feb 22-25; Boston (MA). Abstract #775.
   Google Scholar
• Oomeer S, Singh S, Marcus R, et al. Darunavir in pregnancy: a multicenter retrospective analysis. Poster presented at: 21st Annual Conference of the British HIV Association; 2015 Apr; Brighton, UK. [Poster 50].
   Google Scholar
• Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84(3):248–253.
   PubMedGoogle Scholar
• Papageorgiou I, Grepper S, Unadkat JD. Induction of hepatic CyP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013;41(2):281–290.
   PubMed Web of Science ®Google Scholar
• Spencer L, Neely M, Mordwinkin N, et al. Intensive pharmacokinetics of zidovudine, lamivudine and atazanavir and HIV-1 viral load in breast milk and plasma of HIV + women receiving HAART. In: Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections (CROI); 2009 Feb 8-11; Montreal, Canada. Abstract #942.
   Google Scholar
• Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN study. Antivir Ther. 2014;19(6):587–595.
   PubMed Web of Science ®Google Scholar
• Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS. 2010;24(14):2193–2200.
   PubMed Web of Science ®Google Scholar
• Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27(5):739–748.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Brochot A, Tomaka FL, et al. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. J Antimicrob Chemother. 2014;69(10):2591–2605.
   PubMed Web of Science ®Google Scholar
• French National Institute for Health and Medical Research; French National Agency for Research on AIDS and Viral Hepatitis. Prevention of perinatal transmission of HIV-1 without nucleoside reverse transcriptase inhibitors (MONOGEST). In: clinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Dec 9]. Available from: http://clinicaltrials.gov/show/NCT02738502 NLM Identifier: NCT02738502
   Google Scholar
• Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25(13):1611–1618.
   PubMed Web of Science ®Google Scholar
• Moodley T, Moodley D, Sebitloane M, et al. Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. BMC Pregnancy Childbirth. 2016;16:35.
   PubMed Web of Science ®Google Scholar
• De Ruiter A, Taylor GP, Clayden P, et al. British HIV association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med. 2014;15(Suppl 4):1–77.
   PubMedGoogle Scholar
• Mandelbrot L, Duro D, Belissa E, et al. Placental transfer of darunavir in an ex vivo human cotyledon perfusion model. Antimicrob Agents Chemother. 2014;58(9):5617–5620.
   Google Scholar
• European Collaborative Study, Swiss mother and child HIV cohort study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14(18):2913–2920.
   PubMed Web of Science ®Google Scholar
• Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195–1201.
   PubMed Web of Science ®Google Scholar
• Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506–514.
   PubMed Web of Science ®Google Scholar
• Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis. 2012;54(9):1348–1360.
   PubMed Web of Science ®Google Scholar
• Mesfin YM, Kibret KT, Taye A. Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis. Reprod Health. 2016;13:30.
   PubMed Web of Science ®Google Scholar
• Beckerman K, Albano J, Cohan D, et al. Exposure to combination antiretroviral (cARV) regimens containing protease inhibitors (PI) during pregnancy and prevalence of low birth weight/preterm delivery (LBW/PTD) among women with low pre-existing risk for LBW/PTD: a stratified analysis of 10,082 prospective reports of live births in the Antiretroviral Pregnancy Registry (APR), 1989-2010. Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2009; Cape Town, South Africa.
   Google Scholar
• Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010;201(7):1035–1044.
   PubMed Web of Science ®Google Scholar
• Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20(18):2345–2353.
   PubMed Web of Science ®Google Scholar
• Phiri K, Williams PL, Dugan KB, et al. Antiretroviral therapy use during pregnancy and the risk of small-for-gestational-age birth in a Medicaid population. Pediatr Infect Dis J. 2015;34(7):e169–e170.
   PubMed Web of Science ®Google Scholar
• Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337–2339.
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Schmid CH, Jamieson DJ, et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21(5):607–615.
   PubMed Web of Science ®Google Scholar
• Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105(8):836–848.
   PubMedGoogle Scholar
• Wedi CO, Kirtley S, Hopewell S, et al. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. Lancet HIV. 2016;3(1):e33–48.
   PubMed Web of Science ®Google Scholar
• Williams PL 1, Crain MJ 2, Yildirim C. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48–55.
   PubMed Web of Science ®Google Scholar